Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation phase I/II study of intravitreal Y400 in neovascular age-related macular degeneration
CTR20231778Phase 2Active
- Sponsor
- China Medical System Holdings Limited
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Y400 in exudative macular degeneration, sponsored by China Medical System Holdings Limited. Started Aug 2023; status: active.
02
Drugs
Y400
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20231778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231778.